CryoLife Posts Record Quarterly Revenues of $30... ( ATLANTA April 28 2011 /- CryoLife In...)

CryoLife Posts Record Quarterly Revenues of $30.2 Million

Date:4/28/2011

ATLANTA, April 28, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the first quarter of 2011. Revenues for the first quarter increased 2 percent to a quarter record of $30.2 million compared to $29.7 million for the first quarter of 2010.

"We continue to post record quarterly revenues and generate strong operating cash flow, allowing us to invest in our internal product pipeline and pursue strategic business development opportunities," stated Steven G. Anderson, president and chief executive officer. "With last year's acquisition of worldwide manufacturing and distribution rights to PerClot®, and the pending acquisition of Cardiogenesis, we are repositioning the Company for accelerated revenue and earnings growth."

Net income for the first quarter of 2011 was $1.7 million, or $0.06 per basic and fully diluted common share, compared to net income of $1.9 million, or $0.07 per basic and fully diluted common share, for the first quarter of 2010. Excluding pretax expenses of $1.2 million related to the Company's proposed acquisition of Cardiogenesis and other business development activities, non-GAAP adjusted net income for the first quarter of 2011 was $2.4 million, or $0.09 per basic and fully diluted common share.

Preservation service revenues for the first quarter of 2011 increased 1 percent to $15.7 million compared to $15.6 million for the first quarter of 2010. The increase in preservation service revenues for the first quarter of 2011 was primarily due to an increase in vascular tissue average service fees and an increase in shipments of vascular tissues, largely offset by a decrease in shipments of cardiac tissues.

Product revenues, which consist primarily of sales of BioGlue®, P
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. CryoLife Launches BioGlue® Surgical Adhesive in Japan
2. CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results
3. CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation
4. CryoLife Commences Tender Offer for All Outstanding Shares of Cardiogenesis Corporation
5. CryoLife Signs Definitive Agreement to Acquire Cardiogenesis
6. CryoLife Posts Record Annual Revenues of $116.6 Million
7. CryoLife Announces Release Date and Teleconference Call Details for 2010 Fourth Quarter and Year End Financial Results
8. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
9. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
10. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
11. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive

Post Your Comments:

(Date:5/19/2013)... May 20, 2013 Whole-cell pertussis vaccines were more ... during a large recent outbreak, according to a new ... pertussis vaccines, also called DTwP, were available from the ... that ultimately led to the development of acellular pertussis ... 1990s, the United States had ...

(Date:5/18/2013)... YORK , May 18, 2013 ... law firm, is investigating potential securities fraud at ... AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... Company and its executives violated federal securities laws ... the Company,s Phase III drug trials for Tivopath ...

(Date:5/17/2013)... , May 17, 2013 Sorrento Therapeutics, ... its Fast-Track Advanced Technology Small Business Technology Transfer ... of Allergy and Infectious Diseases (NIAID), a division ... the development of novel human antibody therapeutics to ... or Staph) infections, including methicillin-resistant S. ...

Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2 Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3 Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4 Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4

[0] Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak [0] Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm [0] Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases

... today reported one year,survival results from a Phase I/II ... in combination with dacarbazine in,patients with unresectable stage III ... cohort of patients in both the Phase I and,Phase ... the entire patient,set and a 22 month overall mean ...

... (NYSE:,AZN) today announced that the company has submitted ... U.S. Food and Drug,Administration (FDA) for once-daily SEROQUEL ... the treatment of manic,episodes associated with bipolar disorder ... disorder., The bipolar mania submission is based ...

Cached Medicine Technology:AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 2 AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 3 AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 4 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 2 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 3 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 4 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 5 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 6 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 7

AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression

(Date:5/20/2013)... (PRWEB) May 20, 2013 Medicare Part ... overwhelmingly satisfied, citing lower costs, convenient access to pharmacies ... Hart Research Associates released today by the Pharmaceutical Care ... seniors (9.5 million) are currently enrolled in plans with ... choices, and overall value of plans with preferred pharmacy ...

(Date:5/20/2013)... 2013 Today, Allayo announced the debut ... A mobile application called Allie helps health care consumers ... takes to arrange for quality health care. Ideal for ... of mobile technology and access to personalized service from ... their health care needs are being met. Allie is ...

(Date:5/20/2013)... Cliff Lake Dental Care is pleased to announce ... when visiting the dentist office . The change was made ... , Here are the new office hours: Mondays- 8 a.m. to ... a.m. to 1 p.m. and 2-5 p.m., Thursdays 7 a.m. to ... be open to take appointments only. Cliff Lake Dental wants to ...

(Date:5/20/2013)... improved health care and significant reductions in drug costs ... between physicians and drug company representatives who promote the ... This system, which has been in place for decades, ... to date on new medications, and always provided generous ... the newest drugs, as well as other supplies and ...

(Date:5/20/2013)... (PRWEB) May 20, 2013 A ... Business Intelligence solutions, i2i Systems announced ... Award-winning Southcentral Foundation (SCF) selected i2iTracks as their ... help them meet their Meaningful Use (MU), Government ... System (UDS) requirements – a welcomed solution to ...

Breaking Medicine News(10 mins):Health News:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2 Health News:Allayo Debuts Virtual Health Assistant At HealthBeat 2013 2 Health News:Cliff Lake Dental Care Announces Office Hours Change 2 Health News:Breakup of physician, drug company relationship could improve health care, cut cost 2 Health News:Breakup of physician, drug company relationship could improve health care, cut cost 3 Health News:Baldrige Award Winner Southcentral Foundation Selects i2iTracks Population Health Intelligence Solution to Support Meaningful Use, GPRA and UDS Reporting Requirements 2 Health News:Baldrige Award Winner Southcentral Foundation Selects i2iTracks Population Health Intelligence Solution to Support Meaningful Use, GPRA and UDS Reporting Requirements 3

[0] Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices [0] Allayo Debuts Virtual Health Assistant At HealthBeat 2013 [0] Cliff Lake Dental Care Announces Office Hours Change [0] Breakup of physician, drug company relationship could improve health care, cut cost [0] Baldrige Award Winner Southcentral Foundation Selects i2iTracks Population Health Intelligence Solution to Support Meaningful Use, GPRA and UDS Reporting Requirements

... most common breast cancer uses the most efficient, powerful ... that system kills it, researchers report. This method ... patients, particularly those resistant to standard therapies such as ... Human estrogen receptor-positive breast cancer cells thriving in a ...

... The second generation drug-eluting stent, everolimus-eluting stent ... in randomised controlled trials over the first ... earlier studies comparing EES with another first ... only demonstrated the non-inferiority of EES; the ...

... order to meet future demands for new pharmaceuticals, ... is dependent on the ongoing development of effective ... Because they are so versatile, organometallic molecules are ... reagents containing zinc atoms have certain advantages over ...

... , MONDAY, Aug. 29 (HealthDay News) -- Boxing ... encourage their kids to find sports that don,t focus ... Those are conclusions from the new policy statement from ... Society that recommends that pediatricians vigorously oppose children participating ...

... Meeting & OTO EXPO of the American Academy of Otolaryngology ... of ear, nose, and throat doctors in the world, will ... more than 386 scientific research sessions, 468 posters, and several ... a unique opportunity for journalists from around the world to ...

... 28 (HealthDay News) -- Although it may sound sweet ... behavior, similar to arguing or slinging insults, Canadian scientists ... Queens University in Kingston, Ontario, also revealed that differences ... live, play a role in how aggressive their shouting ...

Research aims to starve breast cancer cells Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents New salts for chemical soups Pediatric Groups Want to KO Boxing for Kids 2011 AAO-HNSF poster presentations Sweet Sparrow Songs May Actually Be Shouting Matches

... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...

... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...

... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...

... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...

Medicine Products:

Alligator Micro-Grasper Atraumatic Grasper Reddick Grasper Long Dolphin Nose Grasper